CompletedInterventional · Phase 2NCT02266745 ↗A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
CompletedInterventional · Phase 1/2NCT03689699 ↗Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate CancerDavid M NanusPIInterventionDrug: Nivolumab · Drug: Degarelix · Drug: BMS-986253DatesOct 2018 – Sep 2023· Results postedSponsorColumbia University Medical CenterProstate CancerAdenocarcinoma of the Prostate
CompletedInterventional · Phase 1/2NCT03888612 ↗A Phase 1/2, Open-label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients With Metastatic Castration Resistant Prostate CancerCora SternbergPIInterventionDrug: ARV-110DatesMar 2019 – Apr 2024SponsorArvinas, Inc.Prostate Cancer Metastatic
CompletedInterventional · Phase 1/2NCT03910660 ↗Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma PhenotypeScott T. TagawaPIInterventionDrug: BXCL701 plus Pembrolizumab · Drug: BXCL701 monotherapyDatesFeb 2019 – Oct 2023SponsorBioXcel Therapeutics, Inc.Prostate CancerNeuroendocrine TumorsSmall Cell Carcinoma
CompletedInterventional · Phase 1/2NCT04037254 ↗Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)David A. GreenPIInterventionBiological: Gonadotrophin Releasing Hormone · Radiation: Intensity-Modulated Radiation Therapy · Drug: NiraparibDatesOct 2019 – Jul 2024· Results postedSponsorNRG OncologyProstate AdenocarcinomaStage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8+4 more
CompletedInterventional · Not applicableNCT04220983 ↗PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate CancerSilvia Chiara FormentiPIInterventionRadiation: MR-Guided Prostate SBRTDatesJan 2020 – Feb 2023· Results postedSponsorWeill Medical College of Cornell UniversityMetastatic Prostate Cancer
CompletedInterventional · Not applicableNCT04571840 ↗A Study Comparing Bi-parametric MRI to Multi-parametric MRI in the Diagnosis of Clinically Significant Prostate CancerDaniel MargolisPIInterventionDiagnostic test: Multiparametric MRI +/- prostate biopsy · Diagnostic test: Biparametric MRI +/- prostate biopsyDatesMar 2022 – Dec 2024 (est.)SponsorUniversity College of LondonProstate Cancer
CompletedInterventional · Early phase 1NCT04576871 ↗Pilot Study of PSMA-TRT Re-treatment Utilizing 225Ac-J591Scott T. TagawaPIInterventionDrug: 225Ac-J591DatesOct 2020 – Aug 2023SponsorWeill Medical College of Cornell UniversityProstate Cancer
CompletedInterventional · Phase 2NCT04600336 ↗A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation TherapyScott T. TagawaPIInterventionDrug: Oxybutynin Chloride · Drug: Placebo Administration · Other: Quality-of-Life Assessment · Other: Questionnaire AdministrationDatesOct 2021 – Feb 2024· Results postedSponsorAlliance for Clinical Trials in OncologyProstate Carcinoma
CompletedInterventional · Phase 1/2NCT04685811 ↗Evaluation of a 68Ga Small Molecule PSMA Antagonist Produced by Two Different MethodsJoseph Reginald OsbornePIInterventionDrug: 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotronDatesDec 2020 – Jun 2021· Results postedSponsorWeill Medical College of Cornell UniversityMetastatic Prostate Adenocarcinoma
CompletedInterventional · Not applicableNCT04815876 ↗Randomized Trial Comparing Transperineal vs. Transrectal MRI-targeted Prostate Biopsy; Randomized Controlled Trial Assessing Transperineal Prostate Biopsy to Reduce Infection ComplicationsJim C. HuPIInterventionProcedure: Transperineal MRI-guided prostate biopsy · Procedure: Transrectal MRI-guided prostate biopsy · Drug: Antibiotic (prophylaxis)DatesJun 2021 – Oct 2025· Results postedSponsorWeill Medical College of Cornell UniversityInfection
CompletedInterventional · Not applicableNCT04843566 ↗Evaluation of Transperineal Biopsy Under Local Anesthesia, a Novel Approach to Decrease Post-Biopsy Infections and Improve Cancer DetectionJim C. HuPIInterventionProcedure: Transperineal MRI-guided prostate biopsy · Procedure: Transrectal MRI-guided prostate biopsy · Drug: Antibiotic (prophylaxis)DatesMar 2021 – Apr 2024· Results postedSponsorWeill Medical College of Cornell UniversityInfection
CompletedObservationalNCT04890314 ↗Prostate Cancer - Comparative Outcomes of New Conceptual Paradigms for TreatmentJim C. HuPIInterventionOther: Patient-reported questionnaireDatesMay 2021 – Apr 2024· Results postedSponsorWeill Medical College of Cornell UniversityProstate Cancer
CompletedInterventional · Not applicableNCT04972097 ↗Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue in an Intermediate-Risk Patient PopulationTimothy McClurePIInterventionDevice: Irreversible ElectroporationDatesMar 2022 – Aug 2024· Results postedSponsorAngiodynamicsProstate Cancer